Can you take Dyclonine / menthol topical with Granisetron?

Granisetron has a moderate potential interaction with Arrhythmia.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Cardiovascular Conditions and Disorders.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Constipation.

Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.

Granisetron has a moderate potential interaction with Electrolyte Abnormalities.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Gastrointestinal Obstruction.

Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.

The dyclonine topical in dyclonine / menthol topical has a moderate potential interaction with Heart Block.

Dyclonine is absorbed rapidly through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic toxicity. Cardiovascular adverse effects include depression of myocardium, hypotension, bradycardia, and cardiac arrest. Therapy with dyclonine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded.

Granisetron has a moderate potential interaction with Neutropenia.

Serious or severe injection site reactions have been reported with the subcutaneous formulation of granisetron. Patients who are neutropenic may be at greater risk; monitor for injection site reactions during treatment and consider discontinuing therapy for severe or persistent reactions.

Granisetron has a moderate potential interaction with Renal Dysfunction.

The subcutaneous formulation of granisetron should be avoided in patients with severe renal dysfunction. In patients with moderate renal dysfunction, subcutaneous granisetron should not be administered more frequently than once every 14 days because the clinical significance of potential prolonged elimination of the polymer vehicle is unknown.

The dyclonine topical in dyclonine / menthol topical has a moderate potential interaction with Shock.

Dyclonine is absorbed rapidly through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic toxicity. Cardiovascular adverse effects include depression of myocardium, hypotension, bradycardia, and cardiac arrest. Therapy with dyclonine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded.